Answers are grounded in this paper and cite their sources.
Accumulation of senescent cells is increasingly viewed as a significant contributor to aging and age-related diseases. To date, the elimination of senescent cells through small molecule senolytic agents has largely relied on a limited number of repurposed agents, often leveraged from previous oncological applications. Here, we describe a CRISPR-based, genome-wide, synthetic lethal screen for senescent cells. From this screen, we identify a number of genes whose deletion appears to be well tolerated in normal proliferating cells, but whose deletion is lethal in the context of senescence. We further characterize one promising candidate gene encoding the ER-resident protein PARP16. Knockdown of PARP16 does not affect the viability of mouse or human cells but results in the death of a wide range of senescent cells. Furthermore, two distinct small molecule PARP16 inhibitors have little effect of normal cell growth but result in the selective death of senescent cells in culture and in freshly isolated human donor lung tissue explants. Together, these results demonstrate a rational strategy to identify novel senolytic therapies that could have potential applications for a wide range of age-related conditions.
No takes yet. Share an insight, caveat, or question.
Ghosh-Choudhary et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: